NUVAX THERAPEUTICS 2.2. Therapeutic Vaccination
2.2.1. Therapeutic Antitumor Efficacy of Cellular Therapy at Low Doses
We evaluated two different doses of transfected cells, 5 × 105 or 2 × 106 per dose, per mouse. The vaccination groups were: (a) control (the same volume of only DMEM as that employed to resuspend cells in each dose); (b) B16-p2FØ, 2 × 106; (c) B16-GM-CSF, 5 × 105; (d) B16-GM-CSF, 2 × 106; (e) B16-GM-CSF + B7.2, 5 × 105; and (f) B16-GM-CSF + B7.2, 2 × 106.
As seen in Figure 6, all treatment groups reached a difference with the highest degree of significance versus the control group, but the best treatments were GM-CSF alone and especially combined with the B7.2 molecule, with the dose of 2 × 106 cells. The GM+B7.2/2 group showed tumor growth inhibition equal to or greater than 80% with respect to the control group. In addition, GM + B7.2/2 significantly differed in the two last days with GM/2 (p < 0.001).
Toxins 2012, 4 1066
Figure 6. Inhibition of tumor growth in cell treatment at low doses. C57BL/6 mice (n = 5 per group) were vaccinated after tumor implantation (day 0, 2 × 104 B16 wild type cells) 3, 10 and 17 days. Treatment groups were control (only DMEM) or 5 × 105 or 2 × 106 cells transfected with plasmid p2F (Ø, GM-CSF, GM-CSF + B7.2). The tumor’s size was measured. The symbol * represents a statistically significant difference (p < 0.001) with respect to the control group. In turn, “+” corresponds to the maximum statistical difference, p < 0.001, “++” to p < 0.01, and “+++” to p < 0.05, with respect to the B16-GM-CSF + B7.2/2 group
News 
Market Data 
Discover 
